GH Research PLC (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders. The company is currently advancing GH001, an inhalable bufotenin product candidate, as a potential treatment for treatment-resistant depression (TRD). GH Research's competitors include other biopharmaceutical companies working on mental health treatments, such as Compass Pathways and MindMed.
On January 5, 2026, Eddie Hickman from Guggenheim set a price target of $29 for GHRS, indicating a potential upside of approximately 83.5% from the current stock price of $15.80. Guggenheim reiterated a Buy rating on GHRS following a management call, as highlighted by StreetInsider. This optimistic outlook is supported by recent positive developments for the company.
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on GH Research's Investigational New Drug Application (IND) for GH001. This decision is a significant milestone, allowing the company to advance its global pivotal program in 2026. Dr. Velichka Valcheva, CEO of GH Research, emphasized the importance of this clearance in positioning GH001 as a potential ultra-rapid and durable treatment for TRD.
In February 2025, GH Research announced that its Phase 2b trial for GH001 successfully met its primary endpoint. The trial demonstrated a significant reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score, with a decrease of 15.2 points from baseline on Day 8, compared to an increase of 0.3 points in the placebo group. This positive outcome supports the potential efficacy of GH001.
The stock for GHRS is currently priced at $15.78, reflecting a significant increase of 19.18% with a change of $2.54. The stock has fluctuated between a low of $15.59 and a high of $19 today. Over the past year, GHRS has reached a high of $20.50 and a low of $7.98. The company's market capitalization stands at approximately $978.8 million, with a trading volume of 4,619,702 shares.
